{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:03:15Z","timestamp":1794895395350,"version":"4.9.1"},"reference-count":95,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management.<\/jats:p>","DOI":"10.3390\/ijms24119388","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T15:30:47Z","timestamp":1685287847000},"page":"9388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?"],"prefix":"10.3390","volume":"24","author":[{"given":"Patricia","family":"Richter","sequence":"first","affiliation":[{"name":"Department of Rheumatology, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-9289","authenticated-orcid":false,"given":"Anca","family":"Cardoneanu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta","family":"Dima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"\u201cSf. Spiridon\u201d Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-0937","authenticated-orcid":false,"given":"Ioana","family":"Bratoiu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"\u201cSf. Spiridon\u201d Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-4685","authenticated-orcid":false,"given":"Alexandra Maria","family":"Burlui","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiana","family":"Costin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-867X","authenticated-orcid":false,"given":"Luana Andreea","family":"Macovei","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u201cGrigore T Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1573397113666170704102444","article-title":"Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus","volume":"13","author":"Tselios","year":"2017","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MCP.0000000000000791","article-title":"The Other Connective Tissue Disease-Associated Interstitial Lung Diseases: Sjogren\u2019s Syndrome, Mixed Connective Tissue Disease, and Systemic Lupus Erythematosus","volume":"27","author":"Lee","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1177\/09612033221122158","article-title":"Serologic Phenotypes Distinguish Systemic Lupus Erythematosus Patients Developing Interstitial Lung Disease and\/or Myositis","volume":"31","author":"Cotton","year":"2022","journal-title":"Lupus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/157339710791330759","article-title":"Systemic Lupus Erythematosus-Related Interstitial Lung Disease","volume":"6","author":"Mittoo","year":"2010","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_5","first-page":"294","article-title":"Pulmonary Manifestations in Systemic Lupus Erythematosus: Pleural Involvement, Acute Pneumonitis, Chronic Interstitial Lung Disease and Diffuse Alveolar Hemorrhage","volume":"14","year":"2018","journal-title":"Reumatol. Clin. (Engl. Ed.)"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.rcl.2022.06.003","article-title":"Imaging of Pulmonary Manifestations of Connective Tissue Disease","volume":"60","author":"Kallianos","year":"2022","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_7","first-page":"S308","article-title":"Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody","volume":"66","author":"Vaseer","year":"2014","journal-title":"ACR Meet. Abstr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13075-018-1776-8","article-title":"Primary Respiratory Disease in Patients with Systemic Lupus Erythematosus: Data from the Spanish Rheumatology Society Lupus Registry (RELESSER) Cohort","volume":"20","author":"Borrell","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"610257","DOI":"10.3389\/fmed.2020.610257","article-title":"Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus","volume":"7","author":"Amarnani","year":"2020","journal-title":"Front. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rdc.2009.03.003","article-title":"Pathophysiology and Clinical Spectrum of Infections in Systemic Lupus Erythematosus","volume":"35","author":"Cuchacovich","year":"2009","journal-title":"Rheum Dis. Clin. N. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"h6819","DOI":"10.1136\/bmj.h6819","article-title":"Management of Interstitial Lung Disease Associated with Connective Tissue Disease","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1038\/s41598-019-43782-7","article-title":"Analysis of Systemic Lupus Erythematosus-Related Interstitial Pneumonia: A Retrospective Multicentre Study","volume":"9","author":"Enomoto","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1759720X211037519","DOI":"10.1177\/1759720X211037519","article-title":"Natural History and Screening of Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disorders","volume":"13","author":"Panagopoulos","year":"2021","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Shin, J.I., Lee, K.H., Park, S., Yang, J.W., Kim, H.J., Song, K., Lee, S., Na, H., Jang, Y.J., and Nam, J.Y. (2022). Systemic Lupus Erythematosus and Lung Involvement: A Comprehensive Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11226714"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13038","DOI":"10.1111\/sji.13038","article-title":"CX3CR1 Might Be a Promising Predictor of Systemic Lupus Erythematosus Patients with Pulmonary Fibrosis","volume":"94","author":"Qiu","year":"2021","journal-title":"Scand. J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00005-015-0356-8","article-title":"The Role of CXC Chemokines in Pulmonary Fibrosis of Systemic Lupus Erythematosus Patients","volume":"63","author":"Fendler","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1191\/0961203303lu1024oa","article-title":"Tumour Necrosis Factor and Other Proinflammatory Cytokines in Systemic Lupus Erythematosus: A Rationale for Therapeutic Intervention","volume":"13","author":"Aringer","year":"2004","journal-title":"Lupus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00296-006-0268-3","article-title":"Lupus Patients with Pulmonary Involvement Have a Pro-Inflammatory Cytokines Profile","volume":"27","author":"Raghupathy","year":"2007","journal-title":"Rheumatol. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.semarthrit.2020.07.011","article-title":"Risk of Interstitial Lung Disease in Patients with Newly Diagnosed Systemic Autoimmune Rheumatic Disease: A Nationwide, Population-Based Cohort Study","volume":"50","author":"Ng","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.resinv.2019.04.005","article-title":"Clinical Features of Interstitial Pneumonia Associated with Systemic Lupus Erythematosus","volume":"57","author":"Toyoda","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.semarthrit.2018.01.010","article-title":"Pulmonary Manifestations in Late versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis","volume":"48","author":"Medlin","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccm.2010.05.001","article-title":"Pulmonary Manifestations of Systemic Lupus Erythematosus","volume":"31","author":"Kamen","year":"2010","journal-title":"Clin. Chest Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.20452\/pamw.2963","article-title":"Clinical Picture of Late-Onset Systemic Lupus Erythematosus in a Group of Polish Patients","volume":"125","author":"Jeleniewicz","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0961203307079042","article-title":"Systemic Lupus Erythematosus in a Multiethnic US Cohort LUMINA XLVIII: Factors Predictive of Pulmonary Damage","volume":"16","author":"Bertoli","year":"2007","journal-title":"Lupus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-79-1-37","article-title":"Diffuse Interstitial Lung Disease in Systemic Lupus Erythematosus","volume":"79","author":"Eisenberg","year":"1973","journal-title":"Ann. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0049-0172(90)90057-M","article-title":"Clinical Associations of Antiribonucleoprotein Antibodies in Patients with Systemic Lupus Erythematosus","volume":"20","author":"Groen","year":"1990","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/anr.1780321007","article-title":"A Meta-Analysis of the Clinical Manifestations of Older-Onset Systemic Lupus Erythematosus","volume":"32","author":"Ward","year":"1989","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.46497\/ArchRheumatol.2020.7583","article-title":"Association of Interstitial Lung Disease with Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus","volume":"35","author":"Chen","year":"2020","journal-title":"Arch. Rheumatol."},{"key":"ref_29","first-page":"266","article-title":"Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia","volume":"53","author":"Xia","year":"2021","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.cpm.0000197403.64631.de","article-title":"Collagen Vascular Diseases of the Lung","volume":"13","author":"Frankel","year":"2006","journal-title":"Clin. Pulm. Med."},{"key":"ref_31","first-page":"2254","article-title":"Bronchiolitis Obliterans Organizing Pneumonia as an Initial Manifestation in Patients with Systemic Lupus Erythematosus","volume":"24","author":"Min","year":"1997","journal-title":"J. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2559.2004.01896.x","article-title":"Variations in Histological Patterns of Interstitial Pneumonia between Connective Tissue Disorders and Their Relationship to Prognosis","volume":"44","author":"Tansey","year":"2004","journal-title":"Histopathology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/096120339500400217","article-title":"Lymphocytic Interstitial Pneumonitis in a Patient with Systemic Lupus Erythematosus","volume":"4","author":"Yood","year":"1995","journal-title":"Lupus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.berh.2009.01.002","article-title":"Respiratory Manifestations of Systemic Lupus Erythematosus: Old and New Concepts","volume":"23","author":"Medeiros","year":"2009","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00063198-200009000-00007","article-title":"Interstitial Lung Disease in Systemic Lupus Erythematosus","volume":"6","author":"Cheema","year":"2000","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1568-9972(03)00090-9","article-title":"Pulmonary Disease in Systemic Lupus Erythematosus and the Antiphospholpid Syndrome","volume":"3","author":"Paran","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.rdc.2014.12.002","article-title":"Histopathology of Lung Disease in the Connective Tissue Diseases","volume":"41","author":"Vivero","year":"2015","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2214\/ajr.166.2.8553934","article-title":"High-Resolution Chest CT in Systemic Lupus Erythematosus","volume":"166","author":"Fenlon","year":"1996","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_39","unstructured":"Jordan, C.E., Reyes-Caballero, K.S., Samson, M.J.T., and Lichauco, J.J. (2021). TP33. TP033 CASE REPORTS IN AUTOIMMUNE LUNG DISEASE, American Thoracic Society."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Marcu, D.T.M., Adam, C.A., Mitu, F., Cumpat, C., Aursulesei Onofrei, V., Zabara, M.L., Burlacu, A., and Crisan Dabija, R. (2023). Cardiovascular Involvement in Tuberculosis: From Pathophysiology to Diagnosis and Complications\u2014A Narrative Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030432"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1685537","article-title":"Pulmonary Complications of Systemic Lupus Erythematosus","volume":"40","author":"Hannah","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_42","first-page":"4233","article-title":"Clinical Features and Independent Predictors of Interstitial Lung Disease in Systemic Lupus Erythematosus","volume":"9","author":"Lian","year":"2016","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Di Bartolomeo, S., Alunno, A., and Carubbi, F. (2021). Respiratory Manifestations in Systemic Lupus Erythematosus. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030276"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e210183","DOI":"10.1148\/ryct.2021210183","article-title":"Interstitial Pulmonary Fibrosis in Systemic Lupus Erythematosus: Are There Variants of the Variant Fibrotic Patterns?","volume":"3","author":"White","year":"2021","journal-title":"Radiol. Cardiothorac. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.lpm.2010.11.004","article-title":"Pleural and Pulmonary Involvement in Systemic Lupus Erythematosus","volume":"40","author":"Torre","year":"2011","journal-title":"Presse. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13244-022-01243-2","article-title":"Clinical and Radiological Features of Lung Disorders Related to Connective-Tissue Diseases: A Pictorial Essay","volume":"13","author":"Palmucci","year":"2022","journal-title":"Insights Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","unstructured":"Gorthi, R., Attoti, Y., Atluri, R., and Mwangi, J.K. (2020). D38. CASE REPORTS IN AUTOIMMUNE LUNG DISEASE, American Thoracic Society. American Thoracic Society International Conference Abstracts."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccm.2019.06.001","article-title":"Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome","volume":"40","author":"Kokosi","year":"2019","journal-title":"Clin. Chest Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Vacchi, C., Sebastiani, M., Cassone, G., Cerri, S., Della Casa, G., Salvarani, C., and Manfredi, A. (2020). Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020407"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/acr.22589","article-title":"Treatment Algorithms in Systemic Lupus Erythematosus","volume":"67","author":"Muangchan","year":"2015","journal-title":"Arthritis Care Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3904\/kjim.2016.212","article-title":"Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease: The Pulmonologist\u2019s Point of View","volume":"32","author":"Koo","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0049-0172(90)90094-V","article-title":"A Long-Term Study of Interstitial Lung Disease in Systemic Lupus Erythematosus","volume":"20","author":"Weinrib","year":"1990","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_54","first-page":"e19218","article-title":"Belimumab in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease: Case Report and Literature Review","volume":"13","author":"Mwangi","year":"2021","journal-title":"Cureus"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in Severe, Treatment-Refractory Interstitial Lung Disease","volume":"19","author":"Keir","year":"2014","journal-title":"Respirology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00296-020-04545-0","article-title":"Rituximab Effect in Severe Progressive Connective Tissue Disease-Related Lung Disease: Preliminary Data","volume":"40","author":"Dorca","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/art.1780370318","article-title":"Treatment of Lupus Interstitial Lung Disease with Intravenous Cyclophosphamide","volume":"37","author":"Eiser","year":"1994","journal-title":"Arthritis Rheum."},{"key":"ref_58","first-page":"967","article-title":"Successful Treatment of Interstitial Lung Disease in Systemic Lupus Erythematosus with Methotrexate","volume":"22","author":"Fink","year":"1995","journal-title":"J. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate Mofetil Is Safe, Well Tolerated, and Preserves Lung Function in Patients with Connective Tissue Disease-Related Interstitial Lung Disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1445-5994.2006.01055.x","article-title":"Rituximab Use in Systemic Lupus Erythematosus Pneumonitis and a Review of Current Reports","volume":"36","author":"Lim","year":"2006","journal-title":"Intern. Med. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/s10165-007-0554-2","article-title":"Intermittent Intravenous Cyclophosphamide Pulse Therapy for the Treatment of Active Interstitial Lung Disease Associated with Collagen Vascular Diseases","volume":"17","author":"Okada","year":"2007","journal-title":"Mod. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/1346-8138.12461","article-title":"Successful Experience of Rituximab Therapy for Systemic Sclerosis-Associated Interstitial Lung Disease with Concomitant Systemic Lupus Erythematosus","volume":"41","author":"Sumida","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1111\/jdv.14192","article-title":"Pirfenidone Combined with Corticosteroids in a Patient with Systemic Lupus Erythematosus-Associated Interstitial Lung Disease","volume":"31","author":"Yang","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1177\/0961203320958055","article-title":"Severe Pulmonary Arterial Hypertension and Interstitial Pneumonia Related to Systemic Lupus Erythematosus Successfully Treated with Mycophenolate Mofetil: A Novel Case Report","volume":"29","author":"Nawata","year":"2020","journal-title":"Lupus"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/2397198320903867","article-title":"Pathogenesis of Systemic Sclerosis Associated Interstitial Lung Disease","volume":"5","author":"Nihtyanova","year":"2020","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive Skin Fibrosis Is Associated with a Decline in Lung Function and Worse Survival in Patients with Diffuse Cutaneous Systemic Sclerosis in the European Scleroderma Trials and Research (EUSTAR) Cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The Identification and Management of Interstitial Lung Disease in Systemic Sclerosis: Evidence-based European Consensus Statements","volume":"2","author":"Maher","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/BOR.0000000000000741","article-title":"Detection, Screening, and Classification of Interstitial Lung Disease in Patients with Systemic Sclerosis","volume":"32","author":"Molberg","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_73","first-page":"e60300","article-title":"Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"160","author":"Chung","year":"2020","journal-title":"J. Vis. Exp."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ebata, S., Yoshizaki-Ogawa, A., Sato, S., and Yoshizaki, A. (2022). New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154631"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/BOR.0000000000000795","article-title":"Treatment for systemic sclerosis-associated interstitial lung disease","volume":"33","author":"Roofeh","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102978","DOI":"10.1016\/j.autrev.2021.102978","article-title":"Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence","volume":"20","author":"Vonk","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13075-021-02555-2","article-title":"Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity","volume":"23","author":"Cutolo","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2020.1751402","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial","volume":"31","author":"Kuwana","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial","volume":"79","author":"Seibold","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.resinv.2020.10.005","article-title":"Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial","volume":"59","author":"Azuma","year":"2021","journal-title":"Respir. Investig."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.41576","article-title":"ffect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"73","author":"Maher","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2022-222564","article-title":"Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from SENSCIS-ON","volume":"81","author":"Allanore","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100\u2009Weeks: Data From a Randomized Controlled Trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/keac535","article-title":"Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: Data from the SENSCIS trial","volume":"62","author":"Denton","year":"2022","journal-title":"Rheumatology"},{"key":"ref_90","first-page":"S143","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter","year":"2022","journal-title":"Rheumatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13075-021-02710-9","article-title":"Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): A joint model analysis","volume":"24","author":"Kreuter","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score","volume":"74","author":"Kuwana","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-022-02095-6","article-title":"Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects","volume":"23","author":"Maher","year":"2022","journal-title":"Respir. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1093\/rheumatology\/keac091","article-title":"Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial","volume":"61","author":"Volkmann","year":"2022","journal-title":"Rheumatology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1759720X211032437","DOI":"10.1177\/1759720X211032437","article-title":"Interstitial lung disease pathology in systemic sclerosis","volume":"13","author":"Konopka","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:43:43Z","timestamp":1760125423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":95,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24119388"],"URL":"https:\/\/doi.org\/10.3390\/ijms24119388","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,28]]}}}